{"id":8016,"date":"2022-04-28T08:36:25","date_gmt":"2022-04-28T06:36:25","guid":{"rendered":"https:\/\/semmelweis.hu\/gyermekklinika2\/?page_id=8016"},"modified":"2026-03-25T14:04:30","modified_gmt":"2026-03-25T13:04:30","slug":"all-ic","status":"publish","type":"page","link":"https:\/\/semmelweis.hu\/tuzoltoklinika\/en\/researches\/all-ic\/","title":{"rendered":"ALL-IC REL"},"content":{"rendered":"

Background<\/a>
\nSteering Committee<\/a>
\nNational Coordinators<\/a>
\nTreatment Guidance and Data Registry<\/a>
\nResults<\/a>
\nMini-Symposia<\/a>
\nHow to Join<\/a><\/p>\n

<\/a><\/p>\n

BACKGROUND<\/strong><\/h4>\n

The Acute Lymphoblastic Leukaemia Inter Continental (ALL-IC) Study Group has completed its second frontline ALL trial. By standardizing therapy and involving flow cytometry based MRD in treatment stratification, patient outcomes improved further. Still 15-20% of patients relapse. When looked up in 2013, survival of relapsed patients in the ALL-IC Study Group lagged behind that achieved in best contemporary studies. Hence, a project was initiated by Prof. Janez Jazbec specifically dedicated to improve ALL 1st<\/sup> relapse results. This is the ALL-IC REL project, by the ALL-IC REL Study Group. There is much but not total overlap between countries \/ centres joining the 1st<\/sup> line ALL-IC trials and the ALL-IC REL project.<\/p>\n

Back to Top \u2191<\/a><\/div>\n

<\/a><\/p>\n

Steering committee<\/strong><\/h4>\n